<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00611442</url>
  </required_header>
  <id_info>
    <org_study_id>C.2007.188</org_study_id>
    <secondary_id>IND 78254</secondary_id>
    <nct_id>NCT00611442</nct_id>
  </id_info>
  <brief_title>Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy</brief_title>
  <official_title>Single Dose Lubiprostone Along With Split-dose PEG Solution Without Dietary Restrictions for Bowel Cleansing Prior to Colonoscopy, a Randomized, Double-blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brooke Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brooke Army Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary outcomes of this procedure will be: 1. The cleanliness of the prep as measured by
      the Ottawa Scale (attachment a). Secondary outcomes will be: 1. Patient satisfaction with the
      prep measured by 5 point Likert scale (attachment b); 2. Procedure time; 3. The number and
      size of polyps detected on examination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Overall Cleanliness of the Prep as Measured by the Ottawa Scale</measure>
    <time_frame>measured upon completion of the colonoscopy, colonoscopies completed during the course of the study (approximately 4 month period)</time_frame>
    <description>Bowel cleansing was evaluated with the Ottawa bowel preparation scale by each endoscopist during the endoscopy. Neither the endoscopist nor the endoscopy nurse was aware of the bowel preparation used prior to the colonoscopy. The Ottawa bowel preparation scale is a validated tool and was used in this study to provide a reliable quality assessment of the bowel preparation used for colonoscopy. This validated scale rates each section of the colon, the right, the mid, and the rectosigmoid colon, on a 5-point scale (0-4), as well as a global 3-point rating for overall colonic fluid (0-2). The total score ranges from 0 to 14. An excellent preparation with little fluid would score 0-3, a good preparation 4-6, while scores higher than 7would indicate progressively worsening bowel preparations. A completely unprepared colon would score 11-14, depending on the amount of colonic fluid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With the Prep Measured by 5 Point Likert Scale</measure>
    <time_frame>measured after completion of the bowel preparation and prior to the colonoscopy, completed during the course of the study (approximately 4 month period)</time_frame>
    <description>The participants completed a survey prior to the colonoscopy that graded their overall satisfaction with the bowel preparation. The subjects rated the survey questions on a 5-point Likert scale where 1 = severely distressing, 2=distressing, 3=bothersome, 4=mild, and 5=none.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>measured upon completion of the colonoscopy, colonoscopies completed during the course of the study (approximately 4 month period)</time_frame>
    <description>Procedure time refers to the total length of time required to complete the colonoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Polyps Detected on Examination</measure>
    <time_frame>measured upon completion of the colonoscopy, colonoscopies completed during the course of the study (approximately 4 month period)</time_frame>
    <description>The number of colon polyps detected during the colonoscopy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Bowel Preparation for Colonoscopy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>split-dose PEG solution without dietary restrictions plus placebo pretreatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lubiprostone</intervention_name>
    <description>lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy</description>
    <arm_group_label>1</arm_group_label>
    <other_name>amitiza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo gelcap, taken at noon the day prior to the colonoscopy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients referred to our clinic for Average or Increased Risk screening for
             Colorectal Cancer

          -  Ages will be from 18 years of age and older

        Exclusion Criteria:

          -  Chronic kidney disease

          -  Previous diagnosis of congestive heart failure

          -  History of bowel obstruction

          -  History of solid organ transplant

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Z Stengel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Harewood GC, Wiersema MJ, Melton LJ 3rd. A prospective, controlled assessment of factors influencing acceptance of screening colonoscopy. Am J Gastroenterol. 2002 Dec;97(12):3186-94.</citation>
    <PMID>12492209</PMID>
  </reference>
  <reference>
    <citation>Tan JJ, Tjandra JJ. Which is the optimal bowel preparation for colonoscopy - a meta-analysis. Colorectal Dis. 2006 May;8(4):247-58. Review.</citation>
    <PMID>16630226</PMID>
  </reference>
  <reference>
    <citation>El Sayed AM, Kanafani ZA, Mourad FH, Soweid AM, Barada KA, Adorian CS, Nasreddine WA, Sharara AI. A randomized single-blind trial of whole versus split-dose polyethylene glycol-electrolyte solution for colonoscopy preparation. Gastrointest Endosc. 2003 Jul;58(1):36-40.</citation>
    <PMID>12838218</PMID>
  </reference>
  <reference>
    <citation>Church JM. Effectiveness of polyethylene glycol antegrade gut lavage bowel preparation for colonoscopy--timing is the key! Dis Colon Rectum. 1998 Oct;41(10):1223-5.</citation>
    <PMID>9788383</PMID>
  </reference>
  <reference>
    <citation>Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin Gastroenterol. 2007 Apr;41(4):345-51. Review.</citation>
    <PMID>17413599</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <results_first_submitted>July 24, 2012</results_first_submitted>
  <results_first_submitted_qc>October 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 1, 2012</results_first_posted>
  <last_update_submitted>October 3, 2012</last_update_submitted>
  <last_update_submitted_qc>October 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brooke Army Medical Center</investigator_affiliation>
    <investigator_full_name>Joel Z. Stengel</investigator_full_name>
    <investigator_title>Gastroenterology Fellow</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Gastroenterology Clinic, Brooke Army Medical Center, Fort Sam Houston, TX October 2007 to January 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Amitiza</title>
          <description>split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>split-dose PEG solution without dietary restrictions plus placebo pretreatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amitiza</title>
          <description>split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>split-dose PEG solution without dietary restrictions plus placebo pretreatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="95"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="191"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="5.2"/>
                    <measurement group_id="B2" value="55.9" spread="4.8"/>
                    <measurement group_id="B3" value="55.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Overall Cleanliness of the Prep as Measured by the Ottawa Scale</title>
        <description>Bowel cleansing was evaluated with the Ottawa bowel preparation scale by each endoscopist during the endoscopy. Neither the endoscopist nor the endoscopy nurse was aware of the bowel preparation used prior to the colonoscopy. The Ottawa bowel preparation scale is a validated tool and was used in this study to provide a reliable quality assessment of the bowel preparation used for colonoscopy. This validated scale rates each section of the colon, the right, the mid, and the rectosigmoid colon, on a 5-point scale (0–4), as well as a global 3-point rating for overall colonic fluid (0–2). The total score ranges from 0 to 14. An excellent preparation with little fluid would score 0–3, a good preparation 4–6, while scores higher than 7would indicate progressively worsening bowel preparations. A completely unprepared colon would score 11–14, depending on the amount of colonic fluid</description>
        <time_frame>measured upon completion of the colonoscopy, colonoscopies completed during the course of the study (approximately 4 month period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amitiza</title>
            <description>split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>split-dose PEG solution without dietary restrictions plus placebo pretreatment</description>
          </group>
        </group_list>
        <measure>
          <title>The Overall Cleanliness of the Prep as Measured by the Ottawa Scale</title>
          <description>Bowel cleansing was evaluated with the Ottawa bowel preparation scale by each endoscopist during the endoscopy. Neither the endoscopist nor the endoscopy nurse was aware of the bowel preparation used prior to the colonoscopy. The Ottawa bowel preparation scale is a validated tool and was used in this study to provide a reliable quality assessment of the bowel preparation used for colonoscopy. This validated scale rates each section of the colon, the right, the mid, and the rectosigmoid colon, on a 5-point scale (0–4), as well as a global 3-point rating for overall colonic fluid (0–2). The total score ranges from 0 to 14. An excellent preparation with little fluid would score 0–3, a good preparation 4–6, while scores higher than 7would indicate progressively worsening bowel preparations. A completely unprepared colon would score 11–14, depending on the amount of colonic fluid</description>
          <units>Ottawa Score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="6.2" lower_limit="3" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With the Prep Measured by 5 Point Likert Scale</title>
        <description>The participants completed a survey prior to the colonoscopy that graded their overall satisfaction with the bowel preparation. The subjects rated the survey questions on a 5-point Likert scale where 1 = severely distressing, 2=distressing, 3=bothersome, 4=mild, and 5=none.</description>
        <time_frame>measured after completion of the bowel preparation and prior to the colonoscopy, completed during the course of the study (approximately 4 month period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amitiza</title>
            <description>split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>split-dose PEG solution without dietary restrictions plus placebo pretreatment</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With the Prep Measured by 5 Point Likert Scale</title>
          <description>The participants completed a survey prior to the colonoscopy that graded their overall satisfaction with the bowel preparation. The subjects rated the survey questions on a 5-point Likert scale where 1 = severely distressing, 2=distressing, 3=bothersome, 4=mild, and 5=none.</description>
          <units>linkert scale (1-5)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.0"/>
                    <measurement group_id="O2" value="3.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Time</title>
        <description>Procedure time refers to the total length of time required to complete the colonoscopy</description>
        <time_frame>measured upon completion of the colonoscopy, colonoscopies completed during the course of the study (approximately 4 month period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amitiza</title>
            <description>split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>split-dose PEG solution without dietary restrictions plus placebo pretreatment</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Time</title>
          <description>Procedure time refers to the total length of time required to complete the colonoscopy</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="5.4"/>
                    <measurement group_id="O2" value="19.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Polyps Detected on Examination</title>
        <description>The number of colon polyps detected during the colonoscopy.</description>
        <time_frame>measured upon completion of the colonoscopy, colonoscopies completed during the course of the study (approximately 4 month period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amitiza</title>
            <description>split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>split-dose PEG solution without dietary restrictions plus placebo pretreatment</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Polyps Detected on Examination</title>
          <description>The number of colon polyps detected during the colonoscopy.</description>
          <units>number of polyps</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Amitiza</title>
          <description>split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>split-dose PEG solution without dietary restrictions plus placebo pretreatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study may be limited by the recruitment of outpatients as the only study participants. The study results might have also been affected by limiting the indication for colonoscopy to colorectal cancer screening.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Joel Stengel</name_or_title>
      <organization>Carl R Darnall Army Medical Center</organization>
      <phone>2545531804</phone>
      <email>joel.stengel@us.army.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

